Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 31.08.2026 1 Adv Sci (Weinh) 1 Am J Transl Res 1 Asian J Endosc Surg 1 Biochim Biophys Acta Gene Regul Mech 1 Biomolecules 1 Biosensors (Basel) 1 BJU Int 1 Bladder Cancer 1 BMC Urol 1 Cancer Treat Res Commun 2 Clin Genitourin Cancer 1 Curr Issues Mol Biol 3 Curr Oncol 1 Diagnostics (Basel) 1 Endocr Pathol 1 Eur J Nucl Med Mol Imaging 2 Eur Urol Oncol 2 Front Immunol 1 Front Med (Lausanne) 2 Front Mol Biosci 1 Front Nutr 1 Front Oncol 4 In Vivo 1 Int J Clin Oncol 2 Int J Mol Sci 1 Int J Urol 5 Int Urol Nephrol 1 J Cell Commun Signal 1 J Cell Mol Med 1 J Clin Med 1 J Gene Med 1 J Surg Oncol 1 J Trace Elem Med Biol 1 J Urol 1 Life (Basel) 1 Medicina (Kaunas) 1 Oncol Ther 2 Urol Oncol 1 Urol Pract 3 Urology 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Sci (Weinh)

1. LI H, Cheng L, Lu X, Dong H, et al
   DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT.
   Adv Sci (Weinh). 2026 Aug 27:e77435. doi: 10.1002/advs.77435.
   PubMed         Abstract available
   
   

   
   Am J Transl Res

2. PENG B, Wang Y, Li H, Zhuang C, et al
   Lipopolysaccharide promotes bladder cancer immunosuppression by disrupting the Tfh/Tfr balance through TLR4 signaling.
   Am J Transl Res. 2026;18:5612-5622.
   PubMed         Abstract available
   
   

   
   Asian J Endosc Surg

3. KAMIYAMA Y, Abe S, Hoshiyama A, Nishikawa Y, et al
   Initial Experience With a Step-Specific Reconstructive Strategy During Robot-Assisted Radical Cystectomy Using the da Vinci SP System.
   Asian J Endosc Surg. 2026;19:e70372.
   PubMed         Abstract available
   
   

   
   Biochim Biophys Acta Gene Regul Mech

4. BAJDAK-RUSINEK K, Wierzbinka M, Sundararajan V, Sieron L, et al
   ESRP2-dependent CD44 isoform switching is functionally linked to epithelial-mesenchymal plasticity in bladder cancer.
   Biochim Biophys Acta Gene Regul Mech. 2026;1869:195180.
   PubMed         Abstract available
   
   

   
   Biomolecules

5. TURGALIYEV A, Konovalov R, Borissenko A, Riethmacher D, et al
   Mechanobiology of Matricellular Proteins in Bladder Cancer: A Narrative Review and Bioinformatics Analysis.
   Biomolecules. 2026;16:1191.
   PubMed         Abstract available
   
   

   
   Biosensors (Basel)

6. HUANG KH, Liu YY, Wu CC, Chen CL, et al
   Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.
   Biosensors (Basel). 2026;16:445.
   PubMed         Abstract available
   
   

   
   BJU Int

7. MIYAJIMA K, Miszczyk M, Roessler N, Inoue S, et al
   Diet and risk of bladder cancer: a systematic review of epidemiological evidence.
   BJU Int. 2026 Aug 23. doi: 10.1111/bju.70435.
   PubMed         Abstract available
   
   

   
   Bladder Cancer

8. SMITH AK, Wittmann D, Emodi K, Dykstra G, et al
   Difficult conversations in bladder cancer survivorship: Integrating mental health and intimacy into routine urologic care.
   Bladder Cancer. 2026;12:23523735261480430.
   PubMed         Abstract available
   
   

   
   BMC Urol

9. SONGLIN L, Yunxun L, Peiyu H, Wen H, et al
   A case report of pathological complete response in an elderly patient with advanced urothelial carcinoma treated with disitamab vedotin plus toripalimab.
   BMC Urol. 2026;26:210.
   PubMed         Abstract available
   
   

   
   Cancer Treat Res Commun

10. COHEN IE, Bruzzi HF, Gontijo GCES, de Carvalho MFSS, et al
    Real-world efficacy and sequential therapy patterns after avelumab maintenance in metastatic urothelial carcinoma: a Brazilian multicenter retrospective cohort study.
    Cancer Treat Res Commun. 2026;48:101368.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

11. DURANT AM, Steffen J, Huelster H, Kaimakliotis H, et al
    Evaluating Circulating DNA as a Prognostic Biomarker in Bladder Cancer Subtypes: A Preliminary Short Report.
    Clin Genitourin Cancer. 2026 Jul 30:102635. doi: 10.1016/j.clgc.2026.102635.
    PubMed        
    
    
12. MERCINELLI C, Basile G, Pastorino GL, Cigliola A, et al
    Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.
    Clin Genitourin Cancer. 2026;24:102638.
    PubMed         Abstract available
    
    

    
    Curr Issues Mol Biol

13. LIU S, Duan L, Wei S
    Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis.
    Curr Issues Mol Biol. 2026;48:825.
    PubMed         Abstract available
    
    

    
    Curr Oncol

14. MUNOZ RA, Medina LG, Kim JS, Supernaw A, et al
    Single-Stoma Cutaneous Ureterostomy After Radical Cystectomy: A Contemporary Narrative Review.
    Curr Oncol. 2026;33:455.
    PubMed         Abstract available
    
    
15. DI LORENZO G, Di Lorenzo S, Verde A, Strianese O, et al
    Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series.
    Curr Oncol. 2026;33:456.
    PubMed         Abstract available
    
    
16. UNE M, Yamamoto S, Fuse H, Yoneoka Y, et al
    Older Age Does Not Have an Impact on Postoperative Complication Risk Following Transurethral Resection of the Bladder Tumor.
    Curr Oncol. 2026;33:457.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

17. VANDER STICHELE A, Van Cleynenbreugel B
    Optical Spectroscopy and Spectral Imaging for Bladder Cancer Detection and Characterisation: A Scoping Review of Diagnostic Evidence and Translational Readiness.
    Diagnostics (Basel). 2026;16:2561.
    PubMed         Abstract available
    
    

    
    Endocr Pathol

18. LOBO A, Cheng L
    Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System.
    Endocr Pathol. 2026;37:36.
    PubMed         Abstract available
    
    

    
    Eur J Nucl Med Mol Imaging

19. LIJNEN RAG, Vierling ML, Ringia JB, Hendricksen K, et al
    Clinical impact of routine second?opinion reading of [(1)(8)F]FDG?PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network.
    Eur J Nucl Med Mol Imaging. 2026 Aug 25. doi: 10.1007/s00259-026-08145.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

20. NOSSING C, Ertl IE, Englinger B
    Rethinking EZH2 Inhibition: A Priming Strategy for EGFR-targeted Therapy in Bladder Cancer.
    Eur Urol Oncol. 2026 Aug 25:S2588-9311(26)00236.
    PubMed        
    
    
21. SCARPA RM
    Re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9:652-9.
    Eur Urol Oncol. 2026 Aug 28:S2588-9311(26)00235.
    PubMed        
    
    

    
    Front Immunol

22. CHEN H, Lin Y, Xue Z, Qie Y, et al
    Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.
    Front Immunol. 2026;17:1929760.
    PubMed         Abstract available
    
    
23. WANG M, Lin M, Wang Y
    CTHRC1(+) cancer associated-fibroblasts promotes malignant progression of bladder cancer cells via inducing an immunosuppressive tumor microenvironment.
    Front Immunol. 2026;17:1898002.
    PubMed         Abstract available
    
    

    
    Front Med (Lausanne)

24. DIAO S, Zhao J, Liu X
    A locally deployed large language model for pathology-informed and nurse-reviewed communication support in bladder cancer immunotherapy.
    Front Med (Lausanne). 2026;13:1903690.
    PubMed         Abstract available
    
    

    
    Front Mol Biosci

25. SOOD A, Martini A, Genitiano P, Rauf M, et al
    Combination treatment with intravesical interferon-alpha gene therapy and an oral pan-ErbB receptor family blocker improves survival in mice with bladder cancer.
    Front Mol Biosci. 2026;13:1804161.
    PubMed         Abstract available
    
    
26. FUKIAGE Y, Okubo N, Taga M, Sato Y, et al
    Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities.
    Front Mol Biosci. 2026;13:1898769.
    PubMed         Abstract available
    
    

    
    Front Nutr

27. ZHANG B, Chen Y, Wang Y, Liu Y, et al
    Summary of the best evidence for whole-course nutritional management of bladder cancer.
    Front Nutr. 2026;13:1916117.
    PubMed         Abstract available
    
    

    
    Front Oncol

28. QIN S, Hong Y, Cheng J, Lv Q, et al
    Spectral CT-derived quantitative imaging parameters combined with inflammatory markers for exploratory preoperative grading of bladder cancer.
    Front Oncol. 2026;16:1892226.
    PubMed         Abstract available
    
    

    
    In Vivo

29. CHEN HX, Liu SL, Huang CP, Hsu YC, et al
    Inflammatory Myofibroblastic Tumor of the Urinary Bladder Presenting as a Radiological cT3 Mass: A Case Report and Narrative Review of 89 Cases.
    In Vivo. 2026;40:3191-3204.
    PubMed         Abstract available
    
    
30. YAMASHITA S, Yasuhara M, Higuchi M, Iwagami S, et al
    Perioperative and Oncological Outcomes of Robot-assisted Versus Open Radical Cystectomy: A Propensity Score-matched Multicenter Study from Japan.
    In Vivo. 2026;40:3098-3105.
    PubMed         Abstract available
    
    
31. WANG MH, Pan MR, Hung YH
    Inhibition of Cyclin-dependent Kinase Counteracts Neuron-promoted Bladder and Endometrial Tumorigenesis: A Systematic Analysis.
    In Vivo. 2026;40:2753-2765.
    PubMed         Abstract available
    
    
32. GUNDOGAR O, Bektas S, Arslan B, Akbas P, et al
    TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival.
    In Vivo. 2026;40:3137-3145.
    PubMed         Abstract available
    
    

    
    Int J Clin Oncol

33. HARA T, Tobe T, Ueki H, Wakita N, et al
    Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.
    Int J Clin Oncol. 2026;31:2025-2032.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

34. LI G, Li D, Lan B, Cheng Y, et al
    Iron Oxide Nanozyme for Magnetothermal Activation of ER-TRPV1 Enables Efficient Intravesical Therapy of Bladder Cancer.
    Int J Mol Sci. 2026;27:7475.
    PubMed         Abstract available
    
    
35. CAMPANELLI G, Parkhomovsky N, Mak CK, Yang C, et al
    MTA1 Regulates EMT and BRAF Signaling Networks in Canine Urothelial Carcinoma.
    Int J Mol Sci. 2026;27:7272.
    PubMed         Abstract available
    
    

    
    Int J Urol

36. FERREIRA WAS, Marchi FA, Vitiello GAF, Villacis RAR, et al
    Cathepsin V (CTSV) Shapes the Epigenetic-Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker.
    Int J Urol. 2026;33:e70609.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

37. CHEN Y, An W, Qu R, Chen C, et al
    Bladder preservation with disitamab vedotin plus PD-1 inhibitors and local intensification in muscle-invasive bladder cancer: a single-center retrospective cohort of 81 patients.
    Int Urol Nephrol. 2026 Aug 28. doi: 10.1007/s11255-026-05316.
    PubMed         Abstract available
    
    
38. CHAI Y, Zhang L, Zhou Y, Dai J, et al
    Concurrent radiosensitising regimens for bladder-preserving radiotherapy in non-metastatic muscle-invasive bladder cancer: a systematic review and structured evidence synthesis with exploratory network meta-analysis.
    Int Urol Nephrol. 2026 Aug 26. doi: 10.1007/s11255-026-05360.
    PubMed         Abstract available
    
    
39. RYTZ MA, Hussung S, Frehner L, Beyer J, et al
    LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study.
    Int Urol Nephrol. 2026 Aug 25. doi: 10.1007/s11255-026-05351.
    PubMed         Abstract available
    
    
40. YOUSSEF HMK, Ibrahim EH, Hasan A, Samman A, et al
    Immunohistochemical assessment of vimentin expression and Ki-67 proliferation index in conventional urothelial carcinoma: a study of 60 Egyptian patients.
    Int Urol Nephrol. 2026;58:3557-3566.
    PubMed         Abstract available
    
    
41. BAKHSH A, Abdullah S, Farghal DM, Badawi AS, et al
    Association of electronic cigarette and conventional smoking with urogenital cancers: NHIS analysis.
    Int Urol Nephrol. 2026;58:3681-3688.
    PubMed         Abstract available
    
    

    
    J Cell Commun Signal

42. GAO J, Ji CX, Ren C, Hines J, et al
    Rapid normal fibroblast-tumor crosstalk promotes cancer-associated fibroblast-like activation and attenuates mitomycin C cytotoxicity in bladder cancer.
    J Cell Commun Signal. 2026;20:e70110.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

43. DONG Y, Xu C, Yan B, Mou S, et al
    Quantitative and Targeted Regulation of Ferroptosis in Bladder Cancer: Preclinical Study.
    J Cell Mol Med. 2026;30:e71333.
    PubMed         Abstract available
    
    

    
    J Clin Med

44. CROITOR A, Cadariu-Brailoiu V, Zbircea AD, Bardan R, et al
    Hyperthermic Intravesical Chemotherapy as a Bladder-Sparing Alternative to BCG in the Management of Non-Muscle-Invasive Bladder Cancer: A Systematic Review of Oncological Outcomes in the Era of BCG Shortage.
    J Clin Med. 2026;15:6352.
    PubMed         Abstract available
    
    

    
    J Gene Med

45. YANG W, Yao L, Wan L, Zhuang C, et al
    CircFut8 Suppresses Bladder Cancer by Modulating SRSF9-Dependent Pre-mRNA Splicing.
    J Gene Med. 2026;28:e70108.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

46. AZEVEDO MFD, Brito PHS, Kallas-Silva L, Liebl B, et al
    Extended Versus Non-Extended Lymphadenectomy in Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    J Surg Oncol. 2026 Aug 26. doi: 10.1002/jso.70334.
    PubMed         Abstract available
    
    

    
    J Trace Elem Med Biol

47. ALI-EL-DEIN B, Abdelgawad M, Abdel-Rahim M, Gomaa IM, et al
    Relationship between concentration of heavy metals in bladder cancer tissue and molecular types using luminal GATA3 and basal cytokeratin 5/6 markers.
    J Trace Elem Med Biol. 2026;97:127944.
    PubMed         Abstract available
    
    

    
    J Urol

48. JOFFE BI, Pingle SR, Laplaca C, Christin JR, et al
    Non-Muscle Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy.
    J Urol. 2026 Aug 26:101097JU0000000000005278. doi: 10.1097/JU.0000000000005278.
    PubMed         Abstract available
    
    

    
    Life (Basel)

49. ZHANG D, Ren H, Bai Y, Han P, et al
    Integrated Mendelian Randomization and Single-Cell Transcriptomics Reveal T Cell Immune Mechanisms in Systemic Lupus Erythematosus-Bladder Cancer Comorbidity.
    Life (Basel). 2026;16:1381.
    PubMed         Abstract available
    
    

    
    Medicina (Kaunas)

50. ARIKAN MG, Arda E, Izol V, Yilmaz H, et al
    Outcomes and Predictive Factors for Gynecologic Organ Involvement in Radical Cystectomy for Female Bladder Cancer Patients: A Multicenter Retrospective Cohort Study.
    Medicina (Kaunas). 2026;62:1609.
    PubMed         Abstract available
    
    

    
    Oncol Ther

51. GRIEBSCH I, Shrestha S, Gotay CC, Gore JL, et al
    Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review.
    Oncol Ther. 2026 Aug 25. doi: 10.1007/s40487-026-00463.
    PubMed         Abstract available
    
    

    
    Urol Oncol

52. SHINOHARA M, Narita T, Hamaya T, Ichiyama T, et al
    A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis.
    Urol Oncol. 2026;44:633-642.
    PubMed         Abstract available
    
    
53. TEIXEIRA EG, Torres LAF, Defante MLR, de Azevedo FM, et al
    Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2026;44:643-651.
    PubMed         Abstract available
    
    

    
    Urol Pract

54. SILVANI C, Abdollah F
    Reply: Incarcerated Patients Present With More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2026 Aug 20:101097UPJ0000000000001062.
    PubMed        
    
    

    
    Urology

55. ROBERSON DS, Wang MK, McLeay Ii MT, Wei N, et al
    A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.
    Urology. 2026;214:35-40.
    PubMed         Abstract available
    
    
56. GOLOMB D, Simard S, Eisner A, Avda Y, et al
    Fear and Health Behavior: The Association Between Fear of Cancer Recurrence and Smoking Cessation.
    Urology. 2026;214:87-92.
    PubMed         Abstract available
    
    
57. ZUBAIR Z, Milenkovski B, Leon AR, Mian M, et al
    "I Don't Feel I Have a Lot of Training in Mental Health...": A Qualitative Assessment of Provider Perspectives on Behavioral Health Support for Patients Undergoing Cystectomy.
    Urology. 2026;214:55-60.
    PubMed         Abstract available
    
    

    
    World J Urol

58. MIRZA W, Hussain K, Anwaar A, Shaikh A, et al
    ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis.
    World J Urol. 2026;44:610.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum